Search results for "Chylomicrons"

showing 10 items of 13 documents

Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene

2010

Chylomicron retention disease is a recessive inherited disorder characterized by fat malabsorption and steatorrhea and is associated with failure to thrive in infancy. We describe a kindred carrying a mutation of Sara2 gene causing a chylomicron retention phenotype. The proband was a 5-month-old baby, born of consanguineous, apparently healthy parents from Morocco, with failure to thrive. There was a large quantity of fats in feces and malabsorption of fat-soluble vitamins. Intestinal biopsies showed a diffused enterocyte vacuolization with large cytosolic lipid droplets. Chylomicron retention disease or Anderson disease was hypothesized, and the Sara2 gene was analyzed by direct sequencing…

AdultMaleProbandmedicine.medical_specialtychylomicron retention disease phenotypic expression Sara2Settore MED/09 - Medicina InternaMalabsorptionEndocrinology Diabetes and MetabolismBiologySettore MED/42 - Igiene Generale E ApplicataExonEndocrinologyMalabsorption SyndromesInternal medicineChylomicronsmedicineHumansAlleleMonomeric GTP-Binding ProteinsGeneticsHaplotypeInfantmedicine.diseaseSteatorrheaPedigreeFat malabsorptionPhenotypeEndocrinologyChild PreschoolMutationFailure to thriveFabry DiseaseFemalemedicine.symptomChylomicron retention diseaseMetabolism
researchProduct

Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increas…

2005

Triglyceride-rich lipoproteins generated during the postprandial phase are atherogenic. Large very low-density lipoproteins (LDLs) or chylomicrons (CMs) are not as atherogenic as their remnants (Rem). Small and dense LDLs are associated with cardiovascular disease. Low-density lipoprotein size is partly under genetic control and is considered as a relatively stable LDL feature. In this article, we present data on retinyl palmitate kinetics correlated with the modification of LDL features in terms of size, density, and in vitro receptor binding affinity after an oral fat load. Six nondiabetic, hypertriglyceridemic (HTG) patients and 6 healthy controls were examined. Low-density lipoprotein s…

AdultMalemedicine.medical_specialtyRetinyl EstersSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBinding CompetitiveModels Biologicalchemistry.chemical_compoundEndocrinologyInternal medicineRetinyl palmitateCell Line TumorChylomicronsmedicineHumansReceptorVitamin AHypertriglyceridemiaLow-density lipoproteins hypertriglyceridemia Fasting and postprandial LDLsTriglycerideCatabolismChemistryFastingFibroblastsPostprandial PeriodDietary FatsLipidsLipoproteins LDLKineticsEndocrinologyPostprandialReceptors LDLlipids (amino acids peptides and proteins)Density gradient ultracentrifugationElectrophoresis Polyacrylamide GelFemaleDiterpenesUltracentrifugationLipoproteinChylomicronMetabolism: clinical and experimental
researchProduct

Luminal Lipid Regulates CD36 Levels and Downstream Signaling to Stimulate Chylomicron Synthesis

2011

International audience; The membrane glycoprotein CD36 binds nanomolar concentrations of long chain fatty acids (LCFA) and is highly expressed on the luminal surface of enterocytes. CD36 deficiency reduces chylomicron production through unknown mechanisms. In this report, we provide novel insights into some of the underlying mechanisms. Our in vivo data demonstrate that CD36 gene deletion in mice does not affect LCFA uptake and subsequent esterification into triglycerides by the intestinal mucosa exposed to the micellar LCFA concentrations prevailing in the intestine. In rodents, the CD36 protein disappears early from the luminal side of intestinal villi during the postprandial period, but …

CD36 AntigensMaleMTPCD36[SDV]Life Sciences [q-bio]BiochemistryMicrosomal triglyceride transfer proteinMice0302 clinical medicineIntestinal mucosaCricetinaeChylomicronsLipoproteinHypertriglyceridemiaMice Knockout0303 health sciencesMitogen-Activated Protein Kinase 3biologyPostprandial PeriodLipid-binding ProteinIntestineApoB48ERKmedicine.anatomical_structurePostprandialBiochemistrylipids (amino acids peptides and proteins)Apolipoprotein B-48MAP Kinase Signaling SystemEnterocyteCHO CellsChylomicron03 medical and health sciencesCricetulusparasitic diseasesmedicineAnimalsRats WistarMolecular Biology030304 developmental biologyUbiquitinationLipid absorptionLipid metabolismCell BiologyLipid MetabolismRatsEnterocytesMetabolismbiology.proteinApolipoprotein B-48CD36[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryChylomicron
researchProduct

From fatty-acid sensing to chylomicron synthesis: Role of intestinal lipid-binding proteins

2013

International audience; Today, it is well established that the development of obesity and associated diseases results, in part, from excessive lipid intake associated with a qualitative imbalance. Among the organs involved in lipid homeostasis, the small intestine is the least studied even though it determines lipid bioavailability and largely contributes to the regulation of postprandial hyperlipemia (triacylglycerols (TG) and free fatty acids (FFA)). Several Lipid-Binding Proteins (LBP) are expressed in the small intestine. Their supposed intestinal functions were initially based on what was reported in other tissues, and took no account of the physiological specificity of the small intes…

CD36 Antigensmedicine.medical_specialtyCD36[SDV]Life Sciences [q-bio]Intestinal adaptationBiologyFatty Acid-Binding ProteinsBiochemistryIntestinal absorptionChylomicronInsulin resistanceLipid-binding proteinsInternal medicineLipid dropletChylomicronsIntestine SmallmedicineAnimalsHumansCd36chemistry.chemical_classificationHypertriglyceridemiaFatty AcidsFatty acidGeneral Medicinemedicine.diseaseLipid MetabolismDietary FatsSmall intestine3. Good healthmedicine.anatomical_structureEndocrinologyEnterocyteschemistryBiochemistryIntestinal AbsorptionIntestinal lipid sensingbiology.proteinlipids (amino acids peptides and proteins)[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChylomicron
researchProduct

Diagnostic algorithm for familial chylomicronemia syndrome

2016

International audience; Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia often associated with recurrent episodes of pancreatitis. The recognition and correct diagnosis of the disease is challenging due to its rarity, and to the lack of specificity of signs and symptoms. Lipid experts, endocrinologists, gastroenterologists, pancreatologists, and general practitioners may encounter patients who potentially have FCS. Therefore, cooperation between experts and improved knowledge of FCS is essential in improving the diagnosis. Currently, a consensus on best practice for the diagnosis of FCS is lacking. Methods: Aiming to def…

Chylomicrons; Familial chylomicronemia syndrome; Hyperlipoproteinemia; Lipoprotein lipase deficiency; Pancreatitis; Biomarkers; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type I; Lipids; Lipoprotein Lipase; Phenotype; Practice Guidelines as Topic; Predictive Value of Tests; Prognosis; Algorithms; Critical Pathways; DNA Mutational Analysis; Decision Support Techniques; Mutation; Internal Medicine; Cardiology and Cardiovascular MedicineSettore MED/09 - Medicina InternaACUTE-PANCREATITIS[SDV]Life Sciences [q-bio]DNA Mutational AnalysisPredictive Value of TestDisease030204 cardiovascular system & hematologyVARIANTSDecision Support Technique0302 clinical medicineDOMAINGenetic MarkerBINDINGChylomicronsHYPERTRIGLYCERIDEMICMedicine030212 general & internal medicinePANCREATITISLipoprotein lipase deficiencyGeneral MedicineFamilial ChylomicronemiaLipidPrognosisLipids3. Good healthAlgorithmDEFICIENCYPhenotypeCritical PathwayPractice Guidelines as TopicCritical PathwaysHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAlgorithmAlgorithmsHumanGenetic MarkersSevere hypertriglyceridemiaFamilial chylomicronemia syndromePrognosiSigns and symptomsLIPOPROTEIN-LIPASEHyperlipoproteinemiaCLASSIFICATIONDecision Support TechniquesSecondary careChylomicronDNA Mutational Analysi03 medical and health sciencesPredictive Value of TestsInternal MedicineMANAGEMENTHumansGenetic Predisposition to DiseasePancreatitibusiness.industryBiomarkerLipoprotein LipaseMutationbusinessBiomarkers
researchProduct

Intestinal CD36 : A long chain fatty acid receptor which controls post prandial hypertriglyceridemia, endotoxemia and intestinal epithelium integrity

2014

Post prandial hypertriglyceridemia represents a risk factor for cardio-vascular diseases and it is associated with metabolic syndrom, obesity, and insulino-resistance. The intestine influences lipid bioavailibility and post prandial hypertriglyceridemia. It controls the quantity and the quality of secreted chylomicrons by adapting its metabolism according to the lipid content of the diet. Nevertheless, the mechanism of dietary lipid detection by the enterocyte is not understood. Our work demonstrates that the transmembrane glycoprotein CD36 is a Long Chain Fatty Acid (LCFA) receptor which triggers ERK1/2 activation. This activation is responsible for the induction of mRNA rate of 3 key prot…

InflammationDietary lipidsIntestin grêle[SDV.AEN] Life Sciences [q-bio]/Food and NutritionERK1/2ChylomicronsEndotoxémieLipides alimentairesCD36EndotoxemiaIntestine
researchProduct

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients Wi…

2018

Objective— Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48). Approach and Results— We performed an in vivo kinetic study with stable isotopes (D 8 -valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d). We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides an…

MaleApolipoprotein B-48Agonistmedicine.medical_specialtymedicine.drug_classhyperlipidemiasGene Expression030209 endocrinology & metabolism030204 cardiovascular system & hematologypatients03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusChylomicronsHyperlipidemiaAnimalsHumansMedicineDiacylglycerol O-AcyltransferaseProspective StudiesTriglycerides[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMice Inbred BALB Cliraglutidebusiness.industryLiraglutideCatabolismType 2 Diabetes Mellitus[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismPostprandial Periodmedicine.diseaseLipoprotein LipaseJejunumEndocrinologyPostprandialAdipose TissueDiabetes Mellitus Type 2kineticsdiabetes mellitusFemaleApolipoprotein B-48Carrier ProteinsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Fermentation Products of Commensal Bacteria Alter Enterocyte Lipid Metabolism

2020

eferred to byJia Wen, John F. RawlsFeeling the Burn: Intestinal Epithelial Cells Modify Their Lipid Metabolism in Response to Bacterial Fermentation ProductsCell Host & Microbe, Volume 27, Issue 3, 11 March 2020, Pages 314-316; International audience; Despite the recognized capacity of the gut microbiota to regulate intestinal lipid metabolism, the role of specific commensal species remains undefined. Here, we aimed to understand the bacterial effectors and molecular mechanisms by which Lactobacillus paracasei and Escherichia coli regulate lipid metabolism in enterocytes. We show that L-lactate produced by L. paracasei inhibits chylomicron secretion from enterocytes and promotes lipid stora…

[SDV.IMM] Life Sciences [q-bio]/ImmunologyEnterocyteBiologyGut floraMicrobiologyCell Linelipids03 medical and health sciences0302 clinical medicineLipid oxidationVirologyChylomicronsmedicineEscherichia coliAnimalsSecretionSymbiosis030304 developmental biology0303 health sciencescommensal bacteriaAMPKLipid metabolismMetabolismLacticaseibacillus paracaseiL-lactatebiology.organism_classificationLipid MetabolismCell biologyIntestinesMice Inbred C57BLmedicine.anatomical_structureEnterocytesFermentation[SDV.IMM]Life Sciences [q-bio]/ImmunologyParasitologyFemalelipids (amino acids peptides and proteins)acetatesmall intestine030217 neurology & neurosurgeryChylomicron
researchProduct

Postprandial adaptation of intestinal lipid metabolism : role of CD36 and PPAR beta

2011

Postprandial hypertriglyceridemia is an emerging risk factor for cardiovascular diseases and is associated with metabolic syndrome, obesity and insulin resistance. The small intestine participates in the postprandial triglyceridemia since both the size and number of secreted chylomicrons modulate lipoprotein lipase activity (LPL). Chylomicron synthesis is a complex mechanism in which the lipidation of Apolipoprotein B48 (ApoB48) by the Microsomal Triglyceride Transfer Protein (MTP) and the transfer between reticulum and Golgi in which the Liver Fatty Acid Binding Protein (L -FABP) is involved are limiting steps. An intestinal fat-mediated adaptation in postprandial period has been demonstra…

[SDV.SA]Life Sciences [q-bio]/Agricultural sciences[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTriglycéridémie postprandialedigestive oral and skin physiologyPostprandial triglyceridemiaRécepteurPPAR betaPPAR béta[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyChylomicronslipids (amino acids peptides and proteins)CD36[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyReceptor
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct